Akorn "With a maturing ANDA pipeline, new opportunities in injectable drug shortages, recent expansion into the OTC ophthalmic segment, in tandem with additional opportunities to enhance its product portfolio through acquisitions, we continue to believe that Akorn is well positioned for 25% annual EPS growth over the next three years," Deutsche Bank analysts wrote in a May 9 report. Shares of Akorn hit a 52-week high Tuesday of $13.25. The stock's 52-week low of $6.18 was set on June 17. Akorn's forward P/E is 18.33; the average for pharmaceutical companies is 35.77. For comparison, Medicis Pharmaceutical ( MRX) has a lower forward P/E of 12.17. Five of the six analysts who cover Akorn rated it buy; one analyst gave the stock a sell rating. The stock has risen 17.27% year to date.